Hunan Fangsheng Pharmaceutical announced that on December 17, 2024, the company's wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. was recognized as a high-tech enterprise, with certificate number GR202444006126, issued on November 28, 2024, valid for three years. After being recognized as a high-tech enterprise, Fangsheng Jianmeng will enjoy the national preferential tax policy for high-tech enterprises, paying corporate income tax at a rate of 15% for three consecutive years. This recognition will not have a significant impact on the company's current operating performance.
方盛制药：子公司方盛健盟被认定为高新技术企业
Hunan Fangsheng Pharmaceutical: The subsidiary Fangsheng Jianmeng has been recognized as a high-tech enterprise.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated